The estimated Net Worth of Annalisa Jenkins is at least $215 Tisíc dollars as of 29 March 2022. Annalisa Jenkins owns over 3,384 units of AvroBio Inc stock worth over $28,498 and over the last 9 years he sold AVRO stock worth over $42,232. In addition, he makes $144,553 as Independent Director at AvroBio Inc.
Sign up
Annalisa Jenkins AVRO stock SEC Form 4 insiders trading
Annalisa has made over 1 trades of the AvroBio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,384 units of AVRO stock worth $42,232 on 29 March 2022.
The largest trade he's ever made was selling 3,384 units of AvroBio Inc stock on 29 March 2022 worth over $42,232. On average, Annalisa trades about 106 units every 0 days since 2015. As of 29 March 2022 he still owns at least 20,356 units of AvroBio Inc stock.
You can see the complete history of Annalisa Jenkins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Annalisa Jenkins biography
Dr. Annalisa M. Jenkins, M.B.B.C., F.R.C.P. serves as Independent Director of the Company. From November 2017 until April 2019, Dr. Jenkins served as the chief executive officer of PlaqueTec Ltd., a biotechnology company focusing on coronary artery disease treatment and prevention. Previously, Dr. Jenkins served as the chief executive officer and a member of the board of directors of Dimension Therapeutics, Inc., a biotechnology company focused on rare and metabolic diseases associated with the liver, from September 2014 until its sale to Ultragenyx Pharmaceutical Inc. in November 2017. From October 2013 to March 2014, Dr. Jenkins served as executive vice president, head of global research and development for Merck Serono Pharmaceuticals, a biopharmaceutical company. Previously, from September 2011 to October 2013, she served as Merck Serono’s executive vice president, global development and medical, and was a member of Merck Serono’s executive committee. Prior to that, Dr. Jenkins pursued a 15-year career at Bristol-Myers Squibb Company, a biopharmaceutical company, where, from July 2009 to June 2011, she was a senior vice president and head of global medical affairs. Dr. Jenkins is currently a committee member of the science board to the FDA, which advises FDA leadership on complex scientific and technical issues. Dr. Jenkins serves on the board of directors of AgeX Therapeutics, Inc. (NYSE American: AGE), Oncimmune Holdings plc (LSE: ONC) and a number of privately held biotechnology and life science companies. Dr. Jenkins previously served on the board of Silence Therapeutics, Ardelyx, Inc. and Sensyne Health plc.
What is the salary of Annalisa Jenkins?
As the Independent Director of AvroBio Inc, the total compensation of Annalisa Jenkins at AvroBio Inc is $144,553. There are 12 executives at AvroBio Inc getting paid more, with Birgitte Volck having the highest compensation of $4,384,270.
How old is Annalisa Jenkins?
Annalisa Jenkins is 54, he's been the Independent Director of AvroBio Inc since 2018. There are 15 older and 4 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.
What's Annalisa Jenkins's mailing address?
Annalisa's mailing address filed with the SEC is COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.
Insiders trading at AvroBio Inc
Over the last 6 years, insiders at AvroBio Inc have traded over $3,066,308 worth of AvroBio Inc stock and bought 2,395,057 units worth $31,037,133 . The most active insiders traders include Braden Michael Leonard, Bruce Booth a Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of $206,675. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth $973,626.
What does AvroBio Inc do?
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
What does AvroBio Inc's logo look like?
Complete history of Annalisa Jenkins stock trades at Ardelyx Inc, OncoSec Medical Inc, AvroBio Inc, AgeX Therapeutics Inc, Mereo BioPharma plc a COMPASS Pathways plc
AvroBio Inc executives and stock owners
AvroBio Inc executives and other stock owners filed with the SEC include:
-
Birgitte Volck,
President - Research & Development -
Erik Ostrowski,
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer -
Geoff MacKay,
President, Chief Executive Officer, Director -
Steven Avruch,
Secretary, Chief Legal Officer -
Geoff MacKay BSc,
Co- Founder, Pres, CEO & Director -
Geoff MacKay,
Co- Founder, Pres, CEO & Director -
Erik Ostrowski M.B.A.,
CFO & Treasurer -
Steven N. Avruch J.D.,
Chief Legal Officer & Sec. -
Philip Vickers,
Independent Director -
Bruce Booth,
Independent Chairman of the Board -
Christopher Paige,
Independent Director -
Phillip Donenberg,
Independent Director -
Annalisa Jenkins,
Independent Director -
Ian Clark,
Independent Director -
Gail Farfel,
Director -
Kim Raineri,
Chief Manufacturing and Technology Officer -
Chris Brinzey,
IR Contact Officer -
Deanna Petersen,
Chief Business Officer -
Dr. Essra Ridha FFPM, M.D.,
Chief Medical Officer -
Andreas Kouri,
Sr. VP of Global Supply Chain & External Manufacturing -
Azadeh Golipour Ph.D.,
Chief Technology Officer -
Deanna M. Petersen MBA,
Chief Bus. Officer -
Dr. Christopher Mason FMEDSCI, FRCS, M.D., Ph.D.,
Chief Scientific Officer -
Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS,
Chief Scientific Officer -
Deanna M. Petersen M.B.A., MBA,
Chief Bus. Officer -
Georgette Verdin,
Chief HR Officer -
Monique Da Silva,
Sr. VP of Corp. Communications -
Dr. Christopher Mason,
Chief Scientific Officer -
Kim Raineri M.B.A.,
Chief Manufacturing & Technology Officer -
Matthew Arnold,
Head of Operations -
Jeffrey Medin Ph.D.,
Scientific Founder -
Venture Fund X, L.P.Atlas V...,
-
Lifesciences Iii, L.P.Claru...,
-
Scott Requadt,
Director -
Vi, Llcsv Life Sciences Fun...,
-
Katina Dorton,
Chief Financial Officer -
Nerissa Kreher,
Chief Medical Officer -
Venture Associates X, L.P. ...,
10% owner -
Lifesciences Iii, L.P.Claru...,
-
Diana Escolar,
Chief Medical Officer -
Christopher Mason,
Chief Scientific Officer -
Essra Ridha,
Chief Medical Officer -
Azadeh Golipour,
Chief Technology Officer -
Braden Michael Leonard,